about
The crystal structure of the complex between a disaccharide anthracycline and the DNA hexamer d(CGATCG) reveals two different binding sites involving two DNA duplexesESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozymeThe x-ray structure of the adduct between NAMI-A and carbonic anhydrase provides insights into the reactivity of this metallodrug with proteinsA gold-containing drug against parasitic polyamine metabolism: the X-ray structure of trypanothione reductase from Leishmania infantum in complex with auranofin reveals a dual mechanism of enzyme inhibitionThe mode of action of anticancer gold-based drugs: a structural perspectiveClioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease.Solution behaviour and biomolecular interactions of two cytotoxic trans-platinum(II) complexes bearing aliphatic amine ligands.2D-DIGE analysis of ovarian cancer cell responses to cytotoxic gold compounds.Challenges associated with metal chelation therapy in Alzheimer's diseaseMetal-based drugs for malaria, trypanosomiasis and leishmaniasis: recent achievements and perspectives.The molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics.Biophysical characterisation of adducts formed between anticancer metallodrugs and selected proteins: new insights from X-ray diffraction and mass spectrometry studies.Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers.Chelation therapy for neurodegenerative diseases.Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies.Metal ion physiopathology in neurodegenerative disorders.Molecular mechanisms and proposed targets for selected anticancer gold compounds.Reactivity and biological properties of a series of cytotoxic PtI2(amine)2 complexes, either cis or trans configured.The disaccharide anthracycline MEN 10755 binds human serum albumin to a non-classical drug binding site.Cytotoxic Profile and Peculiar Reactivity with Biomolecules of a Novel "Rule-Breaker" Iodidoplatinum(II) Complex.[Au2(phen(2Me))2(μ-O)2](PF6)2, a Novel Dinuclear Gold(III) Complex Showing Excellent Antiproliferative Properties.Butyltin(IV) benzoates: inhibition of thioredoxin reductase, tumor cell growth inhibition, and interactions with proteins.Synthesis, structural characterization, solution behavior, and in vitro antiproliferative properties of a series of gold complexes with 2-(2'-pyridyl)benzimidazole as ligand: comparisons of gold(III) versus gold(I) and mononuclear versus binuclear dProteomic analysis of ovarian cancer cell responses to cytotoxic gold compounds.Gold(III) complexes with 2-substituted pyridines as experimental anticancer agents: solution behavior, reactions with model proteins, antiproliferative properties.Mechanistic studies on two dinuclear organogold(III) compounds showing appreciable antiproliferative properties and a high redox stability.Structural and solution chemistry, protein binding and antiproliferative profiles of gold(I)/(III) complexes bearing the saccharinato ligand.Aluminum, copper, iron and zinc differentially alter amyloid-Aβ(1-42) aggregation and toxicity.Structure, solution chemistry, antiproliferative actions and protein binding properties of non-conventional platinum(II) compounds with sulfur and phosphorus donors.Rationalization of the inhibition activity of structurally related organometallic compounds against the drug target cathepsin B by DFT.Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study.Promising in Vitro anti-Alzheimer Properties for a Ruthenium(III) Complex.Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones.Chemistry, antiproliferative properties, tumor selectivity, and molecular mechanisms of novel gold(III) compounds for cancer treatment: a systematic study.Structural characterization, solution studies, and DFT calculations on a series of binuclear gold(III) oxo complexes: relationships to biological properties.Potential pathogenic role of beta-amyloid(1-42)-aluminum complex in Alzheimer's disease.Gold(III) compounds as anticancer agents: relevance of gold-protein interactions for their mechanism of action.Structural and solution chemistry, antiproliferative effects, and DNA and protein binding properties of a series of dinuclear gold(III) compounds with bipyridyl ligands.Antimalarial properties of green tea.Mechanisms of cytotoxicity of selected organogold(III) compounds.
P50
Q27640549-5C477264-3FB9-4090-93B2-224F43F91D25Q27643373-7652DAE9-89D2-4A3E-87A9-29E436E5CFC0Q27664948-24EE6A91-DAD4-4EDB-BEB8-759C4CA7F8DAQ27671675-BF141363-1A02-499B-9844-EDB7B13CACDBQ27686705-09F811E1-54B8-45CB-82AE-B6417EF5EE34Q33429534-68158AE2-DCFE-42D3-BE43-6656010CF986Q33490676-BD1B746F-2640-4E93-8A39-1680B5B0CAA7Q34089015-B067A3A6-E6BE-497B-AEF8-A0281B02D606Q34099450-FF724417-E7FA-4703-9684-DF5C7147E5BAQ34145566-6BA73DB9-C91B-4BE4-8D92-CD76C81EF35BQ34473297-EC2B1BAF-842E-48DD-B753-FEA6B6307A6CQ37090711-0673DDE2-7A79-49BD-AB8A-71FAD679F895Q37340375-871073E6-7DCE-4D67-8A25-B376A0B1EDB7Q37379834-54727205-ECF5-49FB-A409-8D0AD019FBF6Q37563171-B2F421E3-B59E-4BA7-85D0-C9BAC658EBD8Q37641152-ED7E0CEB-9D06-48F5-B663-7D7C90A758B7Q37951055-6491C47A-08C1-478D-AF0A-D188A31915A1Q38328964-D4540CB8-F501-48AD-92AB-10431F010ED6Q38363293-29AC971D-8431-451B-A5BA-0A9E71EFF99CQ39155790-8933C822-D400-4BE0-8BA5-2857A6167DA9Q39159067-F9B649C8-749D-4749-ACA6-24E6B5A9F371Q39217857-F19A5FF4-96E9-49A0-8905-D135096377E4Q39395928-835406BD-7B1E-4CD9-8DA5-6710AA72F738Q39398776-720F93B0-882D-4FEC-9140-A67B38555337Q39427709-E6293D5D-F2C9-4999-81EB-2B15828C9AD9Q39480500-CD8F60AF-E9A7-4DBE-B68C-A8941596E423Q39573372-C96A5753-D014-4B4D-98CB-7B7C1E9B5E37Q39580935-471C7373-4A55-48D2-9ACE-4ADF75809234Q39611155-DCED4E06-5919-4480-A1BF-1E20486EB448Q39704089-64FFDA2E-B52A-410A-BF47-C03EA95D3965Q39746460-7BAD6015-A4F3-4BE9-837A-B07ADE7DD994Q39775009-1D56A794-AD3D-4F10-814D-34419670B353Q39813619-D209A107-87F5-4419-A066-C962DFD6A4EBQ39835123-1E955138-6C49-4485-9DE4-8517385B0D96Q40006619-E5153D36-BCE6-4149-A876-759E8BBDED61Q40039197-C7B55AF9-0131-4E7F-8507-14252DFE2401Q40136607-A6528CEF-B559-4DF4-9B93-0E5DC0711002Q40238048-1C094E35-4CF6-4291-8EC2-620891CA9CA3Q40259466-C67CE802-FE20-4C7F-812C-52A2984D892FQ40362715-8A6BAC69-0E5A-4154-A0F3-3E6A34F49BB4
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Luigi Messori
@ast
Luigi Messori
@en
Luigi Messori
@es
Luigi Messori
@nl
type
label
Luigi Messori
@ast
Luigi Messori
@en
Luigi Messori
@es
Luigi Messori
@nl
prefLabel
Luigi Messori
@ast
Luigi Messori
@en
Luigi Messori
@es
Luigi Messori
@nl
P106
P1153
7004898334
P21
P31
P496
0000-0002-9490-8014